Here, correlation between TBK1 inhibition by amlexanox and AKT/NF-κB axis suggests that the anti-cancer effects of amlexanox are associated with its ability to suppress the proliferation and migration of endometrial cancer cells via the AKT/NF-κB pathway. Here, AKT1 is linked to endometrial cancer.